Immunological Technology that saves lives
A proven, safe, and effective platform of technology that has already saved millions of lives and earned the Lasker award, known as the "American Nobel Prize"
In 1980, Dr. Pollack received the Lasker Award, popularly known as the American Nobel Prize, for excellence in biomedical research. In 1963 he joined and led Ortho Pharmaceutical, a subsidiary of Johnson & Johnson where he worked on his vaccine ideas using a gamma globulin solution known generically as Rh immune globulin. It was safe 100% of the time and worked immediately over 99% of the time, Approved by the FDA as RhoGAM, it went on the market in 1969. Dr. Pollack further developed this platform technology to create an effective instantaneous hyper immunity against Hepatitis B (HBIG). Both RhoGAM and HBIG have been named by the World Health Organization as 'Essential Medicines' accredited for saving millions of lives. Dr. Pollack left Ortho after 25 years and taught immunology at Rutgers and Columbia. Dr. Pollack returned to development, starting a pharmaceutical company of his own with his son David and Dr. Randall Vecchione. Dr. Pollack worked over two decades teaching and honing the technology with his son David. They developed this novel approach, refinement of processes, and continued research and development of the use of human antibody set the foundation of which Quotient's technology is based.
Dr. Pollack passed away in November 3, 2013 at the age of 87.
Click on image (left) to see New York Times article.
Over 500,000 doses are still given annually and estimated at over 250 Million doses have been administered since its release, saving tens of millions of babies - CDC data